Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: June 23, 2022

Inflammatory bowel diseases (IBD), including Crohn’s disease, ulcerative colitis, and unclassified inflammatory are a group of chronic, immune mediated conditions that presumed to occur in genetically susceptible individuals because dysregulated intestinal response environmental factors. IBD patients can be considered subjects with an aberrant makes them at increased risk infections, particularly those due opportunistic pathogens. In many cases this is significantly by the therapy they receive. Aim narrative review describe impact SARS-CoV-2 infection immunogenicity COVID-19 vaccines IBD. Available data indicate do not have susceptibility that, if infected, majority must modify place does negatively affect course. Only corticosteroids should reduced or suspended causing severe forms. Furthermore, seems course mainly on disease psychological factors deriving from measures implemented deal pandemic. The relating induced much less definitive. It certain substantially different seen healthy subjects, exception treated anti-tumor necrosis factor alone combination other immunosuppressants who showed response. How much, however, problem reduces protection known. Moreover, variants has been studied deserves attention. Further studies capable facing solving unanswered questions needed order adequately protect risks associated infection.

Language: Английский

---

SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(23), P. 7238 - 7238

Published: Dec. 6, 2022

The impact of COVID-19 on pediatric patients with inflammatory bowel disease (PIBD) is still not clear and the knowledge acquired over last 2 years evolving. This study aims to investigate risk clinical outcomes in PIBD. A systematic search PubMed Scopus databases was conducted identify studies published up until September 2022. Out 475 articles screened, 14 were included review. Of 4006 children PIBD included, 390 (9.7%) tested positive for COVID-19. Among those COVID-19, 5.9% (0–16.7%) needed hospitalization, 0.6% (0–1%) admitted intensive care unit (PICU), no deaths reported. studies, only four presented details regarding patients’ symptoms, 21% (0–25%) presenting gastrointestinal (GI) symptoms. An association between activity or specific treatment outcome could be established. prevalence low; therefore, initial concerns higher infection worse prognosis this population are supported by currently available data. Further research determine natural history optimal these patients. Much unclear additional should performed order optimize prevention special group

Language: Английский

---

Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders

European Journal of Pediatrics, Journal Year: 2023, Volume and Issue: 182(7), P. 2967 - 2988

Published: April 19, 2023

Coronavirus disease 2019 (COVID-19) infection in pediatric patients with autoimmune disorders is an area of particular concern since diseases can increase the risk complications from virus. However, as rates were significantly higher adults compared to children, this at-risk group children was relatively underrepresented COVID-19 research. The underlying inflammatory basis and medications that affect immune system, such corticosteroids, could severe patients. reportedly lead a variety alterations system. These are plausibly dependent on immune-mediated or prior use immunomodulatory drugs. Patients administrating agents, especially those system dysregulation, experience symptoms COVID-19. Nonetheless, receiving immunosuppressive benefit by preventing cytokine storm syndromes lung tissue damage, threatening outcomes Conclusion: In review, we sought evaluate currently available literature impact its related therapeutic approaches course reflect gaps evidence need for further research field.

Language: Английский

---

Impact of COVID-19 on Pediatric Inflammatory Bowel Diseases—From Expectations to Reality

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(4), P. 399 - 399

Published: April 9, 2024

Viral infections have always been considered a threat to global health, with numerous outbreaks across time. Despite the relative recent experience coronavirus-associated diseases such as severe acute respiratory syndrome (SARS) and Middle East (MERS), syndrome-2’s (SARS-CoV-2) continuous evolution displays different behavior. With tropism for both digestive mucosa, coronavirus disease 2019 (COVID-19) inflammatory bowel (IBD) seem share particular common background. Current literature offers evidence that viral alteration of immune system, intestinal tissue damage, increased permeability, incomplete clearance antigen persistence, dysbiosis, might explain SARS-CoV-2–IBD relationship in terms etiopathogenesis evolution. The hyperinflammatory state entities explains lack success current IBD therapy, raising need new personalized therapeutic options, better outcomes COVID-19 well. This review aims summarize available data on pediatric evolution, management, post-COVID period, an emphasis aspects children.

Language: Английский

---